India’s Sun Pharmaceutical Industries Ltd. is “excited” by the newest findings from late-stage clinical trials with tildrakizumab showing that the biologic delivers “significantly improved” skin clearance in patients with chronic plaque psoriasis, and says the data support the drug’s potential for treating moderate to severe cases of the dermal disease.
Sun’s Tildrakizumab Shines In Pivotal Psoriasis Trials
Sun Pharmaceutical, the world’s fifth-largest specialty generic company, has reported positive results from two pivotal Phase III clinical trials for its psoriasis candidate tildrakizumab, showing that the targeted biologic therapy delivers “significantly improved” skin clearance. While it will face rising competition, some analysts are predicting strong sales
